Dianthus Therapeutics ($DNTH) Insider Trading & Smart Money Activity
Dianthus Therapeutics, Inc. ($DNTH) has 3 insider trades and 8 13F position changes on file. In the last 12 months on the open market, no insider bought and 1 insider sold ($2.03M), net -$2.03M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 1
- Net insider $ (12 mo)
- -$2.03M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 8
- Analyst ratings on file
- 0
DNTH insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 8 / 0 |
| Q3 2026 | 0 | 1 · $2.03M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All DNTH insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Edward CarrCHIEF ACCOUNTING OFFICER | Sell (Open-market sale) 10b5-1 | 20K sh | $2.03M | -10.3% | — | |||||
| Insider | Adam VenessSVP, General Counsel and Sec. | Sell (Option exercise) | 30K sh | +10.9% | +29.0% | — | |||||
| Insider | Adam VenessSVP, General Counsel and Sec. | Buy (Option exercise) | 30K sh | $536.40K | +10.9% | +29.0% | — | ||||
| 13F | Rtw Investments | New | +248.06K sh | $20.36M | +0.4% | -4.2% | Read | ||||
| 13F | Rtw Investments | New | +248.06K sh | $24.18M | +0.4% | -4.2% | Read | ||||
| 13F | Fred Alger Management | Added | +1.13M sh | $95.36M | +0.4% | -4.2% | — | ||||
| 13F | Fred Alger Management | Added | +1.13M sh | $113.26M | +0.4% | -4.2% | Read | ||||
| 13F | Farallon Capital Management | New | +836K sh | $68.61M | +0.4% | -4.2% | — | ||||
| 13F | Farallon Capital Management | New | +836K sh | $81.49M | +0.4% | -4.2% | Read | ||||
| 13F | Baker Bros. Advisors | Added | +62.41K sh | $69.94M | +0.4% | -4.2% | — | ||||
| 13F | Baker Bros. Advisors | Added | +62.41K sh | $83.07M | +0.4% | -4.2% | Read |
1W / 1M / 6M = how DNTH moved from the trade or filing date.
Insider trading in DNTH: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Edward Carr | CHIEF ACCOUNTING OFFICER | 1 | -$2.03M | Sep 17, 2026 | |
| Adam Veness | SVP, General Counsel and Sec. | 2 | — | Jun 17, 2026 |
Institutions moving DNTH (13F)
Frequently asked questions
Are DNTH insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 1 insider made 1 open-market sale worth $2.03M, a net -$2.03M.
What is the latest insider trade in DNTH?
Edward Carr, CHIEF ACCOUNTING OFFICER filed a sell (open-market sale) of 20K sh worth $2.03M on Sep 17, 2026.
Which institutions changed their DNTH positions?
Recent 13F filers moving the stock include Rtw Investments, Fred Alger Management, Farallon Capital Management and Baker Bros. Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.